GSTM1 rs3745453: Understanding Your Detoxification Genetics
The rs3745453 variant is a genetic marker used to identify the functional status of the GSTM1 gene, which plays a key role in how the body processes toxins and certain medications. Research into this variant often focuses on its potential influence on chemotherapy efficacy and individual susceptibility to environmental stressors.
What each genotype means
Functional enzyme activity
You possess at least one functional copy of the GSTM1 gene, which allows your body to produce the glutathione S-transferase M1 enzyme. This enzyme plays a role in neutralizing certain environmental toxins and oxidative stress products. Research into this genotype is ongoing, and you should consult with a healthcare provider regarding any specific concerns about toxin exposure or medication metabolism.
Carried by approximately 40% to 50% of individuals in many global populations, though this varies significantly by ancestry.
Reduced enzyme activity
You carry one functional copy and one non-functional (null) copy of the GSTM1 gene. While you still produce the GSTM1 enzyme, your total capacity for this specific detoxification pathway may be lower than those with two functional copies. As evidence regarding the clinical significance of this variation is limited, please discuss any health concerns or medication-related questions with your clinician or pharmacist.
This heterozygous state is common, appearing in a significant portion of the population alongside the homozygous null and homozygous present genotypes.
Absent enzyme activity
You have a homozygous null genotype, meaning you do not produce the GSTM1 enzyme. Some studies suggest this may be associated with higher markers of oxidative stress or altered responses to certain environmental toxins and chemotherapies, though results are often mixed and depend on other genetic and lifestyle factors. Please discuss your health history and any medication dosing concerns with your doctor or pharmacist.
The null genotype is very common, found in approximately 50% of Caucasian and Asian populations, with a lower prevalence in African and African American populations.
What is the GSTM1 rs3745453 Variant?
The rs3745453 variant is a single-nucleotide polymorphism (SNP) located within the GSTM1 gene region. In genetic research, this marker is frequently used to tag the presence or absence of the GSTM1 gene. The gene is notable for a common structural variation known as a 'null' genotype, where a large portion of the gene is deleted, resulting in a complete loss of the enzyme's activity. Because rs3745453 is closely linked to this structural change, it serves as a proxy for determining whether an individual possesses a functional copy of the gene or the null version. Understanding this variant is part of a broader field of study examining how inherited genetic differences influence the body's ability to neutralize foreign substances, including environmental pollutants and pharmaceutical compounds.
The Role of the GSTM1 Gene
The GSTM1 gene encodes an enzyme belonging to the glutathione S-transferase (GST) family. These enzymes are essential for phase II detoxification, a process where the body attaches glutathione to harmful substances to make them more water-soluble and easier to excrete. By neutralizing electrophilic compounds—which include carcinogens, oxidative stress byproducts, and certain chemotherapy drugs—GSTM1 helps protect cells from damage. When an individual carries the null genotype, they lack the functional GSTM1 enzyme, which may alter their metabolic response to these substances. While the body has other detoxification pathways, the absence of GSTM1 is a subject of ongoing investigation to determine if it leads to increased sensitivity to specific toxins or changes in how patients respond to medical treatments.
Research Associations and Evidence Strength
Scientific literature has explored the association between GSTM1 status and various health outcomes, including cancer susceptibility and drug-induced toxicity. Some studies suggest that the null genotype may be linked to an increased risk of certain cancers, though results are often mixed and can vary significantly by ancestry. In the context of oncology, researchers have investigated whether GSTM1 status influences the efficacy or side effects of chemotherapy, such as platinum-based treatments or anthracyclines. However, the evidence strength for these associations is generally considered limited. Many studies show conflicting results, and it remains unclear whether GSTM1 status alone is a reliable predictor for clinical decision-making. Because these findings are not consistent across all populations or treatment types, this information is currently used primarily for research purposes rather than routine clinical diagnostics.
Population Frequency
The frequency of the GSTM1 null genotype varies widely across different global populations. Research indicates that the null genotype is quite common, appearing in approximately 53% of Caucasian and Asian populations, while it is observed in roughly 16% to 36% of African populations. These variations highlight the importance of considering ancestry when interpreting genetic data. Because the prevalence is so high in many groups, the null genotype is considered a normal variation in human genetics rather than a rare mutation. Understanding these frequency differences is crucial for researchers who study how genetic diversity impacts health outcomes on a global scale.
What You Can Do With This Information
If you have received information about your GSTM1 status, it is important to view it within the context of current scientific uncertainty. Because the evidence linking this variant to specific health outcomes is limited and often inconsistent, it should not be used to make personal health decisions or to predict your response to medications. If you are undergoing medical treatment, such as chemotherapy, and have questions about how your genetics might influence your care, you should discuss this with your oncologist or a clinical pharmacist. They are best equipped to interpret your genetic information alongside your full medical history, lab results, and the specific drugs being used. Never change or stop any prescribed medication based on genetic test results without consulting your healthcare provider.
How common is this variant?
The GSTM1 null genotype is common globally, with frequencies ranging from approximately 16% to 57% depending on the population's ancestral background.
Frequently asked questions
Does the GSTM1 null genotype mean I will get cancer?
No, having the GSTM1 null genotype does not mean you will develop cancer. While some research has explored links between this variant and cancer risk, the evidence is inconsistent and does not establish a direct cause-and-effect relationship.
Should I change my medication based on my GSTM1 status?
You should never change or stop any medication based on genetic test results. Always consult your doctor or pharmacist to discuss how your genetic information relates to your specific treatment plan.
Is GSTM1 testing standard for chemotherapy patients?
GSTM1 testing is not currently a standard clinical requirement for most chemotherapy patients. Its role in predicting treatment response or toxicity is still being researched and is not yet considered a definitive clinical tool.
Why do results for GSTM1 vary between populations?
Genetic variations like the GSTM1 null genotype are distributed differently across the world due to human evolutionary history. These differences in frequency are common and reflect the natural genetic diversity found in human populations.
Sources & further reading
Educational information only, last refreshed 9/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3745453?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in GSTM1
A well-studied variant within the glutathione S-transferase family linked to susceptibility to hypertension and vascular disease.
The GSTM1 null genotype involves a gene deletion that results in a complete loss of enzyme activity, impacting the detoxification of various environmental toxins and drugs.